---

Editorial Board

3

Contents

4

Abstracts of the 19th Annual Meeting of the European Society for Clinical Virology, 14th–17th September 2016, Lisbon

5

Oral Presentations

5

Abstract no: 75 Presentation at ESCV 2016: Oral 1 Medico-economic impact of the rapid diagnosis of influenza in paediatric emergency department by using a new sensitive chromatographic immunoassay

5

Abstract no: 306 Presentation at ESCV 2016: Oral 2 Molecular characterization of human rhinovirus in Portugal: 2014–2015 season

5

Abstract no: 224 Presentation at ESCV 2016: Oral 3 Illuminating influenza epidemiology in Scotland using next generation sequencing

6

Abstract no: 195 Presentation at ESCV 2016: Oral 4 Long-term impairment attributable to congenital cytomegalovirus infection

6

Abstract no: 32 Presentation at ESCV 2016: Oral 5 Severe fetopathy caused by cytomegalovirus recurrence with isolated intra-abdominal complication in an immune woman

7

Abstract no: 349 Presentation at ESCV 2016: Oral 6 Current trends in molecular epidemiology of Varicella-Zoster Virus clinical isolates in Czech republic

7

Abstract no: 174 Presentation at ESCV 2016: Oral 7 Increased detection of enterovirus type D68 associated with acute flaccid paralysis and severe respiratory illness in Wales, January–February 2016

8

Abstract no: 180 Presentation at ESCV 2016: Oral 8 Does a chill cause a cold?

8

Abstract no: 285 Presentation at ESCV 2016: Oral 9 Metagenomic analysis of the respiratory virome associated with acute respiratory illness of unknown etiology in infants

9

Abstract no: 37 Presentation at ESCV 2016: Oral 10 Assumption-free improvement of themaxRatio algorithm increases the accuracy of qPCR assays targeting viruses

9

Abstract no: 202 Presentation at ESCV 2016: Oral 11 Anti-BK virus neutralizing antibody titers before transplantation predict BK virus replication in kidney transplant recipients after transplantation

10

Abstract no: 341 Presentation at ESCV 2016: Oral 12 A longitudinal study on dynamics of plasma neutralising antibodies and its determinants in HIV-2 infected individuals

11

Abstract no: 108 Presentation at ESCV 2016: Oral 13 Implementation of a rapid HIV-1 RNA test in diagnosing acute HIV infections among visitors of the Amsterdam clinic of sexually transmitted infections

11

Abstract no: 129 Presentation at ESCV 2016: Oral 14 Evaluation of HIV-DNA, soluble CD14 and inflammatory markers in HIV-1 positive patients receiving antiretroviral therapy

12

Abstract no: 214 Presentation at ESCV 2016: Oral 15 Detection of a novel EV-A71 subgenogroup C1 recombinant variant emerging in Germany, 2015

13

Abstract no: 104 Presentation at ESCV 2016: Oral 16 Preadolescent patients with atypical course of Zika virus (ZIKV) infection: Clinical findings and quantitative viral detection in saliva and plasma

13

Abstract no: 289 Presentation at ESCV 2016: Oral 17 Enterovirus D68 diagnosed in severe respiratory and neurological illness in children during 2015–2016 season in Portugal

14

Abstract no: 189 Presentation at ESCV 2016: Oral 18 Evaluation of TTV load kinetics among kidney transplant recipients in the first year post-transplant period

14

Abstract no: 344 Presentation at ESCV 2016: Oral 19 Encephalitis caused by a novel adenovirus “orphan genome” in an adult allogenic SCT recipient

15

Abstract no: 250 Presentation at ESCV 2016: Oral 20 Molecular and clinical characterization of Enteroviruses-D68 infections between 2010 and 2015 in Lyon, France using 3D Cell culture and Next-Generation Sequencing

15

Abstract no: 169 Presentation at ESCV 2016: Oral 21 Norovirus molecular epidemiology in a paediatric UK hospital: Unexpected diversity, seasonality and sources of infection

16

Abstract no: 66 Presentation at ESCV 2016: Oral 22 Longer duration of viral shedding following infection with a novel norovirus GII.4 strain

16

Abstract no: 73 Presentation at ESCV 2016: Oral 23 Molecular characterization of long-term shedding of respiratory syncytial viruses isolated from consecutive samples collected in haematological patients

17

Abstract no: 92 Presentation at ESCV 2016: Oral 24 Plasma Torquetenovirus (TTV) DNA load as a surrogate marker of reconstitution of CMV-specific immunity in the allogeneic stem cell transplantation setting

17

Abstract no: 229 Presentation at ESCV 2016: Oral 25 Whole-genome sequencing of adenovirus in immunocompromised paediatric patients directly from clinical samples elucidates molecular epidemiology of suspected outbreaks

18

Abstract no: 290 Presentation at ESCV 2016: Oral 26 Seroprevalence of hepatitis E virus among the Portuguese general population and prevalence of silent infection in blood donors – HEPeCONTROL

18

Abstract no: 322 Presentation at ESCV 2016: Oral 27 Assessment of the Illumina MiSeq massively parallel sequencing platform for simultaneous analysis of Hepatitis C virus resistance to all direct-acting antivirals combination regimes

19

Abstract no: 107 Presentation at ESCV 2016: Oral 28 Hepatitis D virus infection in Slovenian patients with chronic hepatitis B virus infection: A national prevalence study

20

Abstract no: 167 Presentation at ESCV 2016: Oral 29 Antiviral effect of interferons on BK virus infection

20

Abstract no: 231 Presentation at ESCV 2016: Oral 30 High incidence of gancliclovir-resistant cytomegalovirus infections in solid organ transplant patients

21

Abstract no: 116 Presentation at ESCV 2016: Oral 31 A multidrug resistant HSV1 infection occurring under cidofovir treatment for ADV infection in an immunocompromised child: Perspectives to new antiviral drugs

21

Abstract no: 117 Presentation at ESCV 2016: Oral 32 HIV neutralising antibody delivered by gene therapy with a stable retroviral vector encoded in baculovirus expression systems

22

Abstract no: 152 Presentation at ESCV 2016: Oral 33 European non-polio enterovirus surveillance and laboratory detection – Are we prepared to detect an enterovirus outbreak?

22

Abstract no: 43 Presentation at ESCV 2016: Oral 34 Neurotrophic potential of Saffold virus and the effects of its leader protein in the central nervous system of a mouse model

23

Abstract no: 175 Presentation at ESCV 2016: Oral 35 Torque Teno Virus in liver tranplant patients in Scotland, UK

23

Abstract no: 96 Presentation at ESCV 2016: Oral 36 Differences among mumps virus surface proteins between genotype G and other genotypes and their potential effect on mumps virus immunity and pathogenesis

24

Abstract no: 350 Presentation at ESCV 2016: Oral 37 Structural basis of Zika virus cross-reactivity and cross-neutralization with flavivirus post-infection and post-vaccination sera

24

Abstract no: 87 Presentation at ESCV 2016: Oral 38 Zika virus infections in travellers and contacts in Lombardy, Northern Italy 2016

25

Abstract no: 81 Presentation at ESCV 2016: Oral 39 Zika virus infections imported to Portugal, the National Reference Laboratory experience: The importance of sample collection time lapse in diagnosis

25

Poster Presentations 1

26

Abstract no: 103 Presentation at ESCV 2016: Poster 1 Direct fluorescent antibody, focus diagnostics SimplexaTMFlu A/B & RSV and multi-parameter customized respiratory Taqman® Array Card testing in immunocompromised patients

26

Abstract no: 106 Presentation at ESCV 2016: Poster 2 Correlation between a new BioPlex® 2200 ToRC IgM assay and established commercial assays for the detection of IgM antibodies toT. gondii, rubella, and cytomegalovirus

26

Abstract no: 109 Presentation at ESCV 2016: Poster 3 Comparison of the Beckman Coulter DxN VERIS and Abbott RealTime assays in analyzing HCV positive plasma samples

27

Abstract no: 118 Presentation at ESCV 2016: Poster 4 Characterisation and standardisation of material in QCMD EQA programmes in the absence of higher order standards

27

Abstract no: 120 Presentation at ESCV 2016: Poster 5 Performance of the Aptima® HBV Quant assay on the fully automated Panther® system

28

Abstract no: 122 Presentation at ESCV 2016: Poster 6 Verification of the Argene® real time PCR kits on the new eMAGTMextraction platform

28

Abstract no: 123 Presentation at ESCV 2016: Poster 7 External assay controls – How do you monitor yours?

28

Abstract no: 124 Presentation at ESCV 2016: Poster 8 CMV Run control r-gene® (ARGENE® range, bioMérieux): A tool to ensure the reliability of human cytomegalovirus nucleic acid amplification technique results

29

Abstract no: 126 Presentation at ESCV 2016: Poster 9 RNA internal control, a new tool for the rapid development of detection tools by real time PCR in outbreak situation. Application to the detection of Middle East Respiratory Syndrome human coronavirus

29

Abstract no: 131 Presentation at ESCV 2016: Poster 10 Multicentre evaluation of the variability of adenovirus quantification by PCR

30

Abstract no: 132 Presentation at ESCV 2016: Poster 11 Evaluation of two algorithms for diagnosis of Epstein-Barr virus infection

30

Abstract no: 133 Presentation at ESCV 2016: Poster 12 Evaluation of the Veris MDxTMsystem for quantification of Hepatitis B DNA and Hepatitis C and HIV-1 RNA in a medium sized University Hospital

30

Abstract no: 135 Presentation at ESCV 2016: Poster 13 Comparison of standardised and non-standardised serology assays for clinical virology diseases

31

Abstract no: 138 Presentation at ESCV 2016: Poster 14 External in-run controls for gastro-intestinal, respiratory infections and Zika virus that will improve assay standardisation

32

Abstract no: 144 Presentation at ESCV 2016: Poster 15 CXCL13 in patients with facial palsy caused by varicella zoster virus and Borrelia burgdorferi: A comparative study

32

Abstract no: 149 Presentation at ESCV 2016: Poster 16 Evaluation of HPV16-specific central memory T cell response in healthy subjects and patients with head–neck cancer

33

Abstract no: 155 Presentation at ESCV 2016: Poster 17 Evaluation of a rapid test for the detection of Tick Borne Encephalitis (TBE) IgM in serum and CSF

33

Abstract no: 158 Presentation at ESCV 2016: Poster 18 Comparison of in-house TaqMan assay versus the Luminex Multicode technology on the ARIES platform for detection of Influenza A/B and RSV A/B

34

Abstract no: 162 Presentation at ESCV 2016: Poster 19 Antibody detection and qPCR assay for an accurate diagnosis of parvovirus B19 infection

34

Abstract no: 168 Presentation at ESCV 2016: Poster 20 Comparative evaluation of the Aptima HSV 1&2 assay and a lab developed real-time PCR test for detection of HSV-1 and HSV-2 viruses

35

Abstract no: 170 Presentation at ESCV 2016: Poster 21 Plasma and serum are suitable specimen types for quantitation of HCV RNA using real-time transcription mediated amplification or PCR

35

Abstract no: 171 Presentation at ESCV 2016: Poster 22 The modular approach to respiratory syndromic testing with the fully-automated novel Panther Fusion System

36

Abstract no: 176 Presentation at ESCV 2016: Poster 23 Performance evaluation between Seegene Anyplex II RV16 Version 1.1 and Biofire FilmArray Respiratory Panel Version 1.7 for the detection of respiratory viruses

36

Abstract no: 185 Presentation at ESCV 2016: Poster 24 Performance comparison of the new filmarray meningitis/encephalitis panel with routine diagnostic methods

37

Abstract no: 192 Presentation at ESCV 2016: Poster 25 The novel ARIES platform demonstrates simplified molecular workflows and enhanced lab efficiency

37

Abstract no: 196 Presentation at ESCV 2016: Poster 26 Performance of a molecular diagnostic, multicode based, sample-to-answer assay for the simultaneous detection of Influenza A, B and Respiratory Syncytial Viruses

38

Abstract no: 200 Presentation at ESCV 2016: Poster 27 Fully automated diagnosis of MERS-CoV infection in respiratory specimen on the Idylla™ MDx Platform

38

Abstract no: 21 Presentation at ESCV 2016: Poster 28 Flexibility and full automation for clinical sample extraction – Performance evaluation of the new bioMérieux eMAG

39

Abstract no: 212 Presentation at ESCV 2016: Poster 29 Evaluation of the Beckman Coulter DxN VERIS Molecular Diagnostics System (DxN VERIS) for the determination of viral load in plasma from patients infected with either HBV or HIV-1

39

Abstract no: 220 Presentation at ESCV 2016: Poster 30 Performance evaluation of the Aptima® HIV-1 Quant Dx and Aptima® HBV Quant assays on the fully automated Panther in comparison to COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 and HBV tests

39

Abstract no: 232 Presentation at ESCV 2016: Poster 31 Nucleic acid testing of blood donors – Ege University Hospital short term experience

40

Abstract no: 234 Presentation at ESCV 2016: Poster 32 Qualitative detection of Zika virus RNA with the Sentosa® SA ZIKV RT-PCR test

40

Abstract no: 246 Presentation at ESCV 2016: Poster 33 Comparative performance of new Aptima HCV Quant Dx assay with Abbott HCV Real-Time assay

41

Abstract no: 254 Presentation at ESCV 2016: Poster 34 Evaluation of the Aptima HIV-1 Quant Dx assay on a wide panel of HIV-1 strains

42

Abstract no: 264 Presentation at ESCV 2016: Poster 35 CE-IVD validation of EBV ELITe MGB® assay in combination with ELITe InGeniusTM, an innovative sample-to-result solution for in vitro diagnostic

42

Abstract no: 267 Presentation at ESCV 2016: Poster 36 Comparison of respiratory and Meningitis/Encephalitis viruses detected by FilmArray® multiplex PCR versus real-time PCR

43

Abstract no: 273 Presentation at ESCV 2016: Poster 37 Cross-contamination and carry-over study results obtained with ELITe InGenius, a new sample-to-result solution for in vitro diagnostics

43

Abstract no: 279 Presentation at ESCV 2016: Poster 38 Validation of ELITe InGenius™, a flexible sample-to-result solution, for viral meningitis and encephalitis testing

44

Abstract no: 288 Presentation at ESCV 2016: Poster 39 Comparing performance of NxTAG RPP, xTAG RVP Fast v2 and FilmArray RP for detecting respiratory pathogens in nasopharyngeal aspirates and swine/avian origin influenza A in culture isolates

44

Abstract no: 292 Presentation at ESCV 2016: Poster 40 Comparison of the recently launched Hologic Aptima HBV Quant assay with the established Abbott RealTime HBV assay in viral load measurement

45

Abstract no: 30 Presentation at ESCV 2016: Poster 41 Comparison of two quantitative detection assays of cytomegalovirus DNA

45

Abstract no: 304 Presentation at ESCV 2016: Poster 42 Performance of the IDS-iSYS “walk away” immunoassay system for the assessment of immunity to rubella virus and cytomegalovirus

46

Abstract no: 31 Presentation at ESCV 2016: Poster 43 Characterization of oseltamivir-resistant population dynamics in immunosuppressed patients with prolonged excretion using ddPCR platform and comparison with deep sequencing analysis

46

Abstract no: 314 Presentation at ESCV 2016: Poster 44 A new combination of old techniques for HIV disease progression – qRT-PCR and ONEp-PCR

47

Abstract no: 328 Presentation at ESCV 2016: Poster 45 Performance of the IDS-iSYS “walk away” immunoassay system for the determination of Epstein–Barr Virus (EBV) serological status

47

Abstract no: 335 Presentation at ESCV 2016: Poster 46 Evaluation of process control “Mengo Virus” using 3 RNA extraction kits and 2 different types of methods of one-step real-time RT-PCR in Donax sp (Palabritas)

48

Abstract no: 337 Presentation at ESCV 2016: Poster 47 Ion Torrent next generation sequencing for accurate genotyping and detection of resistance associated variants in HCV and HIV

48

Abstract no: 351 Presentation at ESCV 2016: Poster 48 Mass spectrometry of influenza virus using clinically available MALDI-TOF platform

49

Abstract no: 41 Presentation at ESCV 2016: Poster 49 Increasing blood safety by diagnosing Zika, Chikungunya and Dengue in times of massive outbreaks

49

Abstract no: 49 Presentation at ESCV 2016: Poster 50 Newly diagnosed HIV-1 cases: Decreased proportion of recent infections based on a multi-assay algorithm combining two serological assays

50

Abstract no: 50 Presentation at ESCV 2016: Poster 51 Lateral flow immunochromatographic assay for detection of Porcine Respiratory Reproductive Syndrome Virus type 1-specific antibodies

50

Abstract no: 50 Presentation at ESCV 2016: Poster 51 Lateral flow immunochromatographic assay for detection of Porcine Respiratory Reproductive Syndrome Virus type 1-specific antibodies

50

Abstract no: 52 Presentation at ESCV 2016: Poster 52 Random access molecular diagnostics – Increased efficiency in laboratory workflow and translation of reduced result turnaround time to patient benefit

51

Abstract no: 54 Presentation at ESCV 2016: Poster 53 Real-time multiplex PCR system detection of viruses and bacteria in blood from febrile infants <90 days of age

51

Abstract no: 55 Presentation at ESCV 2016: Poster 54 HIV incidence assays: Evaluation of three HIV Avidity enzyme immunoassays

52

Abstract no: 57 Presentation at ESCV 2016: Poster 55 Evaluation of the H-DiaCMVQ kit® for detecting and quantifying CMV-DNA in plasma and in whole blood samples

52

Abstract no: 65 Presentation at ESCV 2016: Poster 56 Use of recombinant virus technology to produce non-infectious, whole process controls for emerging viruses such as Ebola, Chikungunya, Dengue-2, Norovirus GII, MERS-CoV and Zika

53

Abstract no: 67 Presentation at ESCV 2016: Poster 57 Characterisation and standardisation of Qnostic products in the absence of higher order standards

53

Abstract no: 71 Presentation at ESCV 2016: Poster58 Comparison of two multiplexed PCR assays for respiratory virus detection in ICU patients: FilmArray® respiratory panel and AllplexTM respiratory full panel

54

Abstract no: 76 Presentation at ESCV 2016: Poster 59 Evaluation of three different sample populations on a new multiplex BioPlex®2200 assay for the detection of measles, Mumps, and Varicella-Zoster virus IgM antibodies

54

Abstract no: 80 Presentation at ESCV 2016: Poster 60 Paper-based point-of-care testing for cost-effective diagnosis of acute dengue infections

55

Abstract no: 86 Presentation at ESCV 2016: Poster 61 Loop-mediated isothermal amplification for point-of-care diagnosis of viral respiratory tract infection in childhood

55

Abstract no: 91 Presentation at ESCV 2016: Poster 62 Comparison of the performances of the three nucleic acid extraction systems: The Roche Magna Pure LCTM System, the Biomerieux easyMAG® system, and the new Biomerieux eMAG™ System

56

Abstract no: 94 Presentation at ESCV 2016: Poster 63 Comparison of the Hologic Aptima HCV Quant Dx assay to the Roche COBAS Ampliprep/COBAS TaqMan HCV Test v2.0 for the quantification of HCV-RNA in plasma samples

56

Abstract no: 95 Presentation at ESCV 2016: Poster 64 Comparison of the Hologic Aptima HIV-1 Quant Dx assay to the Roche COBAS Ampliprep/COBAS TaqMan HIV-1 Test v2.0 for the quantification of HIV-RNA in plasma samples

57

Abstract no: 98 Presentation at ESCV 2016: Poster 65 Ensuring the quality of polyomavirus diagnosis in immunocompromised patients

57

Abstract no: 127 Presentation at ESCV 2016: Poster 66 Microbiological evaluation of respiratory tract infections in pilgrims returning from countries affected by Middle East respiratory syndrome coronavirus (MERS-CoV)

58

Abstract no: 136 Presentation at ESCV 2016: Poster 67 Determination of genotype distribution and the various polymorphisms in cytomegalovirus (CMV) strains

58

Abstract no: 142 Presentation at ESCV 2016: Poster 68 Appropriate diagnosis of Zika virus infection: Italy North-West experience

59

Abstract no: 164 Presentation at ESCV 2016: Poster 69 Screening of emerging viral infections among risk groups

59

Abstract no: 173 Presentation at ESCV 2016: Poster 70 RIDA®GENE Zika Virus: A new commercial real-time RT-PCR assay for sensitive and reliable detection of zika virus in urine and serum samples

60

Abstract no: 213 Presentation at ESCV 2016: Poster 71 Toscana virus meningitis in Southwestern France

60

Abstract no: 268 Presentation at ESCV 2016: Poster 72 From TYPENED to REGIOtype to EUROtype: Moving towards a comprehensive surveillance strategy for emerging viruses

61

Abstract no: 294 Presentation at ESCV 2016: Poster 73 Multicenter investigation of bufavirus in the etiology of viral central nervous system infections of adults and children

61

Abstract no: 330 Presentation at ESCV 2016: Poster 74 Mumps outbreak among vaccinated students in Trondheim, Norway in 2015

62

Abstract no: 334 Presentation at ESCV 2016: Poster 75 Analytical performance and method comparison of the VERSANT Zika RNA 1.0 Assay (kPCR)

62

Abstract no: 338 Presentation at ESCV 2016: Poster 76 Molecular epidemiology of enterovirus in Scotland, January 2013–December 2015

63

Abstract no: 353 Presentation at ESCV 2016: Poster 77 Ebola virus outbreak in West Africa – Portuguese laboratory response overview

63

Abstract no: 111 Presentation at ESCV 2016: Poster 78 Norovirus genotypes diversity in sporadic cases and in outbreaks of acute gastroenteritis in Spain: A 10-year study

64

Abstract no: 130 Presentation at ESCV 2016: Poster 79 Detection and characterisation of viral pathogens causing gastroenteritis in Ireland, 2014–2016

64

Abstract no: 154 Presentation at ESCV 2016: Poster 80 Phylogenetic analysis of G12 group A rotavirus circulating in Spain during 2012–2015: Detection of different clusters with distinct evolutionary origins

65

Abstract no: 16 Presentation at ESCV 2016: Poster 81 Detection of adenovirus in diarrheal children between 0 and 5 years old and except adenovirus serotype 40/41 by DNA sequencing, and phylogenetic analysis

65

Abstract no: 2 Presentation at ESCV 2016: Poster 82 Bufavirus genotype 3 in Turkish children with severe diarrhoea

66

Abstract no: 203 Presentation at ESCV 2016: Poster 83 Multiplex technology for the detection of gastrointestinal viruses in stool samples from diarrheic children

66

Abstract no: 208 Presentation at ESCV 2016: Poster 84 Comparison of rotavirus frequency and genotype distribution in Rwanda before and after vaccine introduction

67

Abstract no: 230 Presentation at ESCV 2016: Poster 85 Evaluation of VIASURE real-time PCR assays for detection of rotavirus and norovirus GI and GII in fecal samples

67

Abstract no: 25 Presentation at ESCV 2016: Poster 86 Epidemiology of Astrovirus infection in infants in Tehran, Iran

68

Abstract no: 29 Presentation at ESCV 2016: Poster 87 Surveillance of Noroviruses GII.4 variants, GII.3 and GII.17 in acute gastroenteritis patients in Shenzhen, China from 2012 to 2015

68

Abstract no: 293 Presentation at ESCV 2016: Poster 88 Investigation of the role of gastroenteritis causing viruses in the asymptomatic neonatal digestive tract

69

Abstract no: 315 Presentation at ESCV 2016: Poster 89 A paediatrics case with unusual presentation of adenovirus enteritis in immunocompetent host

69

Abstract no: 100 Presentation at ESCV 2016: Poster 90 Hepatitis A virus epidemiology in Turkey as childhood vaccination begins: Seroprevalence and endemicity by region

70

Abstract no: 137 Presentation at ESCV 2016: Poster 91 Evaluation of anti-HCV Line immunoassay indeterminant results

70

Abstract no: 151 Presentation at ESCV 2016: Poster 92 Memory T cells specific for HBV enumerated by a peptide-based cultured enzyme-linked immunospot assay in healthy HBV-vaccinated subjects

71

Abstract no: 159 Presentation at ESCV 2016: Poster 93 Impact of the genotyping method on the distribution of hepatitis C virus subtypes of genotype 1

71

Abstract no: 160 Presentation at ESCV 2016: Poster 94 Hepatitis E virus seroprevalence in East- and West Flanders, Belgium: Comparison between 2011 and 2016

72

Abstract no: 166 Presentation at ESCV 2016: Poster 95 Lyophilising have to create a stable product, is it possible?

72

Abstract no: 177 Presentation at ESCV 2016: Poster 96 Characterization of NS3 region and frequency of resistance mutations against Simeprevir of hepatitis C virus genotype 1a and 1b in Portuguese infected patients

73

Abstract no: 178 Presentation at ESCV 2016: Poster 97 Hepatitis B virus infection and reactivation in two patients with anti-HBs following etanercept therapy and alemtuzumab and rituximab therapies: Case presentation

73

Abstract no: 191 Presentation at ESCV 2016: Poster 98 The distribution of hepatitis C virus genotypes of patients with chronic hepatitis C infection in Eskisehir Region of Turkey

74

Abstract no: 194 Presentation at ESCV 2016: Poster 99 Change in the prevalence of hepatitis E virus in the last 15 years, Turkey

74

Abstract no: 211 Presentation at ESCV 2016: Poster 100 Hepatitis E virus subgenotypes 3i and 3f in wastewater of treatment plants of Portugal

75

Abstract no: 225 Presentation at ESCV 2016: Poster 101 Seroprevalence of hepatitis B in children in Konya region of Turkey

75

Abstract no: 24 Presentation at ESCV 2016: Poster 103 Association of rs731236(Taq1)VDR TT genotype, chronic hepatitis B infection and serum vitamin D level

76

Abstract no: 243 Presentation at ESCV 2016: Poster 104 Clinical evaluation of the Aptima HCV Quant Dx assay for hepatitis C virus RNA quantification on Panther system

76

Abstract no: 251 Presentation at ESCV 2016: Poster 105 Reactivation of hepatitis B virus infection with pazopanib: Lessons for all in caring for co-morbid patients

77

Abstract no: 257 Presentation at ESCV 2016: Poster 106 Enhancing the screening of active hepatitis C virus (HCV) infection through molecular testing of dried-blood spots in a community-based counselling and testing centre in Barcelona

77

Abstract no: 260 Presentation at ESCV 2016: Poster 107 Clinical evaluation of the Aptima HBV Quant assay for hepatitis B virus DNA quantification on Panther system Heiko Petersen1,∗, Joe

78

Abstract no: 261 Presentation at ESCV 2016: Poster 108 Evaluation of a novel assay for hepatitis C virus genotype 1 subtyping

78

Abstract no: 265 Presentation at ESCV 2016: Poster 109 Prevalence of hepatitis delta virus infection among hepatitis b virus surface antigen positive patients diagnosed in a Central Hospital in Portugal, a 5 years retrospective study

79

Abstract no: 270 Presentation at ESCV 2016: Poster 110 Clinical evaluation of the Veris HCV assay for hepatitis C virus RNA quantification

79

Abstract no: 271 Presentation at ESCV 2016: Poster 111 Reconstruction of the regional transmission of HCV in Southern Sweden by phylodynamics

80

Abstract no: 287 Presentation at ESCV 2016: Poster 112 Occupational exposure to hepatitis E virus (HEV) in Portuguese swine workers

80

Abstract no: 295 Presentation at ESCV 2016: Poster 113 Clinical and analytical performance characteristics of the VERSANT HCV RNA 2.0 (kPCR) assay

81

Abstract no: 296 Presentation at ESCV 2016: Poster 114 Hepatitis A and E among asymptomatic pregnant women and acute hepatitis patients from South Tunisia

81

Abstract no: 297 Presentation at ESCV 2016: Poster 115 Detection and genetic characterization of imported hepatitis E virus genotype 1 of probable Indian origin, Portugal, 2016

82

Abstract no: 300 Presentation at ESCV 2016: Poster 116 Preliminary study of the prevalence of hepatitis E virus infection in liver transplant recipients in Portugal

82

Abstract no: 301 Presentation at ESCV 2016: Poster 117 The frequency of occult HBV infection in Eskisehir region of Turkey between 2001 and 2015

83

Abstract no: 317 Presentation at ESCV 2016: Poster 118 Anti-HAV IgG seroprevalence in Lisbon region residents: Preliminary results from the National Serological Survey 2015–2016

83

Abstract no: 331 Presentation at ESCV 2016: Poster 119 Single-step hepatitis C testing: Simplifying the clinical pathway from primary care to specialist services

84

Abstract no: 339 Presentation at ESCV 2016: Poster 120 HEPATITIS E – Reaction or unspecific reaction?

84

Abstract no: 342 Presentation at ESCV 2016: Poster 121 Hepatitis B surface antigen expression: A pilot study comparing wild type and surface antigen mutant viruses

85

Abstract no: 35 Presentation at ESCV 2016: Poster 122 Comparison of immunoassays from three chemiluminescent automated systems for the detection of hepatitis B virus serological markers

85

Abstract no: 352 Presentation at ESCV 2016: Poster 123 Comparative study of DxN VERIS molecular diagnostics system and the COBAS AmpliPrep/COBAS TaqMan platform for the determination of viral load in Hepatitis C virus infected patients

86

Abstract no: 40 Presentation at ESCV 2016: Poster 124 Apolipoprotein(a) inhibits hepatitis C virus entry

86

Abstract no: 5 Presentation at ESCV 2016: Poster 125 Method comparison of VIDAS® ANTI-HBS TOTAL II with three equivalent assays in the 5–40 IU/L range critical for HBV vaccine status establishment

87

Abstract no: 59 Presentation at ESCV 2016: Poster 126 Study of HCV seroprevalence in adult population in the Czech Republic

87

Abstract no: 7 Presentation at ESCV 2016: Poster 127 The Syrian refugees crisis brings challenges to the health authorities in Europe: Hepatitis A Virus is a case in point

88

Abstract no: 89 Presentation at ESCV 2016: Poster 128 Performance of the Aptima® HCV Quant Dx Assay on the Panther® System

88

Abstract no: 93 Presentation at ESCV 2016: Poster 129 Detection of Q80K mutation in HCV NS3 protease gene in Hradec Kralove – Initial experience

89

Abstract no: 99 Presentation at ESCV 2016: Poster 130 Hepatitis B virus vaccination status of medical laboratory workers; a multicentre evaluation in Turkey

89

Poster Presentations 2

90

Abstract no: 110 Presentation at ESCV 2016: Poster 131 Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation

90

Abstract no: 119 Presentation at ESCV 2016: Poster 132 Evaluation of the Aptima HIV-1 Quant Dx Assay using plasma and dried blood spots

90

Abstract no: 141 Presentation at ESCV 2016: Poster 133 Prospective evaluation of Cepheid Xpert HIV-1 Viral Load assay as a supplemental confirmatory HIV-1 test in the routine clinical laboratory setting

91

Abstract no: 17 Presentation at ESCV 2016: Poster 134 Molecular characterization of HIV-1 in HBV±HDV/HCV co-infected HIV-1 positive patients in Turkey

91

Abstract no: 20 Presentation at ESCV 2016: Poster 135 Genotyping of HPV DNA positive and HPV E6/E7 mRNA negative cervical samples with abnormal cytology

92

Abstract no: 205 Presentation at ESCV 2016: Poster 136 Performance of the LIAISON® XL murex recHTLV-I/II assay

92

Abstract no: 210 Presentation at ESCV 2016: Poster 137 The seroprevalence of HBV, HCV and HIV in blood donors

93

Abstract no: 227 Presentation at ESCV 2016: Poster 138 Characterization of Epstein–Barr Virus LMP1 deletion variants by Next-Generation Sequencing in HIV-associated Hodgkin Lymphoma (French ANRS CO16 LYMPHOVIR cohort)

93

Abstract no: 236 Presentation at ESCV 2016: Poster 139 Assessment of laboratory performance in the molecular detection of HIV through International EQA Scheme

94

Abstract no: 244 Presentation at ESCV 2016: Poster 140 Analysis of the mRNA expression of DNA damage response genes in HIV infected patients

94

Abstract no: 305 Presentation at ESCV 2016: Poster 141 Molecular studies on HSV: Replication rate, infection capacity and progeny

95

Abstract no: 318 Presentation at ESCV 2016: Poster 142 Genetic diversity and drug resistance profiles of human immunodeficiency virus type 1 (HIV-1) strains infecting pregnant women in the Greater Lisbon

95

Abstract no: 320 Presentation at ESCV 2016: Poster 143 Substantial increase of newly reported cases of HIV related to MSM in the Czech Republic

96

Abstract no: 327 Presentation at ESCV 2016: Poster 144 Genital herpes in a STD outpatient clinic in Lisbon

96

Abstract no: 33 Presentation at ESCV 2016: Poster 145 Vaginal intraepithelial neoplasia induced by unusual papillomavirus subtype associated with high load of human herpes virus 6

97

Abstract no: 34 Presentation at ESCV 2016: Poster 146 Inflammatory cytokine and gene expression patterns correlate with etiologic agent causing pneumonia among patients with advanced HIV in Medellin, Colombia

97

Abstract no: 347 Presentation at ESCV 2016: Poster 147 The Alere HIV Combo point-of-care test; Useful in clinical practice?

98

Abstract no: 60 Presentation at ESCV 2016: Poster 148 Prevalence of human papilloma virus in HIV-positive patients: A preliminary study

98

Abstract no: 63 Presentation at ESCV 2016: Poster 149 Intermittent HIV-1 low level viremia detection (blips) using the Abbott RealTime HIV assay

99

Abstract no: 64 Presentation at ESCV 2016: Poster 150 Comparison of genotyping tropism test in paired HIV-1 plasma RNA and proviral DNA from Portuguese patients

99

Abstract no: 146 Presentation at ESCV 2016: Poster 151 Case report: Unexpected cause of respiratory failure 3 days after heart transplantation

100

Abstract no: 148 Presentation at ESCV 2016: Poster 152 Respiratory viruses in the intensive care unit: More frequent than expected

100

Abstract no: 161 Presentation at ESCV 2016: Poster 153 Multidrug-resistant cytomegalovirus infection in a pediatric stem cell transplantation patient

100

Abstract no: 172 Presentation at ESCV 2016: Poster 154 Changing time line of CMV infection in seropositive live donor Liver Transplant recipients: A prospective study from a tertiary care liver center

101

Abstract no: 187 Presentation at ESCV 2016: Poster 155 BK virus infections in renal transplant recipients

102

Abstract no: 190 Presentation at ESCV 2016: Poster 156 The impact of viral respiratory infections in the first year post-transplant period of pediatric hematopoietic stem cell transplant (HSCT) recipients

102

Abstract no: 259 Presentation at ESCV 2016: Poster 157 Normalizing ELISPOT to quantify human cytomegalovirus (HCMV) and Epstein Barr-virus (EBV) specific T-cell response in kidney transplant recipients

103

Abstract no: 272 Presentation at ESCV 2016: Poster 158 BK polyomavirus-seroreactivity increases with virus replication

103

Abstract no: 323 Presentation at ESCV 2016: Poster 159 Frequent HHV6 DNA positivity in children with severe burn injury

104

Abstract no: 329 Presentation at ESCV 2016: Poster 160 BK polyomavirus infection activates the type I interferon response in human fibroblasts, depending on the cGAS-STING pathway

104

Abstract no: 333 Presentation at ESCV 2016: Poster 161 Monitoring of cytomegalovirus-specific immunity using the QuantiFERON-CMV assay in hematopoietic cell transplant recipients: Preliminary results

105

Abstract no: 336 Presentation at ESCV 2016: Poster 162 HHV-6 chromosomal integration in allogeneic haematopoietic stem cell transplantation

105

Abstract no: 348 Presentation at ESCV 2016: Poster 163 Monitoring of CMV infection: A comparison of pp65-antigenemia from whole blood and Elisa in Iranian patients undergoing kidney transplantation

106

Abstract no: 39 Presentation at ESCV 2016: Poster 164 Replication of porcine cytomegalovirus in mesenchymal stem cells derived from miniature pig bone marrow and lung

106

Abstract no: 72 Presentation at ESCV 2016: Poster 165 Monitoring of BK and JC polyomavirus viruria and viremia in hematopoietic stem cell transplant (HSCT) and renal transplant (RT) recipients

106

Abstract no: 77 Presentation at ESCV 2016: Poster 166 Torque teno virus (TTV) in immunosuppressed host: Performances studies of TTV R-Gene® kit and donors and recipients kidney samples genotyping

107

Abstract no: 79 Presentation at ESCV 2016: Poster 167 Rapid adenovirus typing method for species identification

108

Abstract no: 12 Presentation at ESCV 2016: Poster 168 Genotyping and full genome sequencing of varicella–zoster viruses isolated from Korean patients

108

Abstract no: 121 Presentation at ESCV 2016: Poster 169 The distribution of enteroviruses isolated in virology laboratory, Singapore General Hospital, 2008–2015

108

Abstract no: 147 Presentation at ESCV 2016: Poster 170 Prevalence of enterovirus in patients with meningitis: 2007–2015

109

Abstract no: 163 Presentation at ESCV 2016: Poster 171 Controlling the quality of diagnostic PCR assays

109

Abstract no: 206 Presentation at ESCV 2016: Poster 172 Evolutionary studies of herpes simplex viruses (HSV) genomes provide evidences of HSV-2/HSV-1 interspecies recombination

110

Abstract no: 242 Presentation at ESCV 2016: Poster 173 Commutability and agreement of international and secondary standards

110

Abstract no: 326 Presentation at ESCV 2016: Poster 174 Half of family doctors do not use the flu vaccine

111

Abstract no: 345 Presentation at ESCV 2016: Poster 175 Prevalence of specific IgGs against the study Rubella Virus in Sao Tome and Principe with “Guthrie Cards”

111

Abstract no: 4 Presentation at ESCV 2016: Poster 176 Investigation of HSV1 positivity of patients with neurological symptoms by real time PCR method

112

Abstract no: 105 Presentation at ESCV 2016: Poster 177 Chickenpox exposure in pregnancy – A comparison of a qualitative and a quantitative varicella zoster virus antibody assay and follow up of patient outcome

112

Abstract no: 219 Presentation at ESCV 2016: Poster 178 Low risk of wild poliovirus importation to Germany via asylum seekers from polio-risk countries: Results of stool screening and serology, 2013–2015

113

Abstract no: 274 Presentation at ESCV 2016: Poster 179 National serological survey – Portugal 2015–2016: Study design

113

Abstract no: 275 Presentation at ESCV 2016: Poster 180 Mobile phones of paediatric senior physicians are highly contaminated with viral genomes of several epidemic viruses during the winter season

114

Abstract No: 280 Presentation at ESCV 2016: Poster 181 National serological survey – Portugal 2015–2016: Rubella seroprevalence in a population-based sample of childbearing age women resident in the North, Lisbon and Algarve

114

Abstract no: 128 Presentation at ESCV 2016: Poster 182 Automation of Luminex NxTAG respiratory pathogen panel

115

Abstract no: 15 Presentation at ESCV 2016: Poster 183 Comparison of viral and epidemiological profiles among hospitalized children with severe acute respiratory diseases in Beijing and Shanghai

115

Abstract no: 150 Presentation at ESCV 2016: Poster 184 The “Snotbarometer”: Epidemiological data on respiratory infections

116

Abstract no: 181 Presentation at ESCV 2016: Poster 185 Molecular characterization of human parainfluenza virus type 3 (HPIV-3) among hospitalized patients from central Israel

116

Abstract no: 182 Presentation at ESCV 2016: Poster 186 Prevalence and genetic characterization of enterovirus D68 among children with severe acute respiratory infection in China

117

Abstract no: 186 Presentation at ESCV 2016: Poster 187 Replication and immune response in HAE of HCoV-HKU1 isolate from a pediatric patient with severe acute respiratory infection

117

Abstract no: 19 Presentation at ESCV 2016: Poster 188 Development of an external quality assessment panel for the molecular detection of respiratory viruses

117

Abstract no: 198 Presentation at ESCV 2016: Poster 189 Genotyping and epidemiology analysis of human rhinovirus among children with severe acute respiratory infection in Shanghai, China 2013–2014

118

Abstract no: 204 Presentation at ESCV 2016: Poster 190 RSV surveillance in Sweden – How can we improve it?

118

Abstract no: 221 Presentation at ESCV 2016: Poster 191 Microarray-based molecular detection of viral pathogens associated with respiratory infections

119

Abstract no: 228 Presentation at ESCV 2016: Poster 192 Detection of influenza viruses from patients in university hospital

119

Abstract no: 233 Presentation at ESCV 2016: Poster 193 An overview of human parainfluenza virus 1-4 infections in northeastern Slovenia based on molecular detection

119

Abstract no: 252 Presentation at ESCV 2016: Poster 194 Seasonality of respiratory syncytial virus infection in the EU/EEA, 2010–2016

120

Abstract no: 253 Presentation at ESCV 2016: Poster 195 Herpes Simplex 1-2 in broncho alveolar fluid: A 5 years retrospective study

121

Abstract no: 255 Presentation at ESCV 2016: Poster 196 Three years (2013–2016) of human respiratory syncytial virus surveillance at a tertiary hospital in Catalonia, Spain

121

Abstract no: 263 Presentation at ESCV 2016: Poster 197 Evaluation of interferon lambda 4 nucleotide polymorphism in infants suffering from bronchiolitis

122

Abstract n◦: 266 Presentation at ESCV 2016: Poster 198 Patterns of respiratory pathogen nasal colonization in the first year of life in healthy infants and infants with cystic fibrosis

122

Abstract no: 269 Presentation at ESCV 2016: Poster 199 Genotyping of rhinoviruses in children and adults during 2014–2016

123

Abstract no: 277 Presentation at ESCV 2016: Poster 200 A cost-efficient solution: Reagent comparison guide for neuraminidase inhibition assay

123

Abstract no: 278 Presentation at ESCV 2016: Poster 201 Evaluation of point of care testing platform (ePLEX) for respiratory viral diagnosis

124

Abstract no: 286 Presentation at ESCV 2016: Poster 202 Single genetic clades of EV-D68 strains in 2010, 2013, and 2015 in Osaka City, Japan

124

Abstract no: 302 Presentation at ESCV 2016: Poster 203 Influenza surveillance during 2015/2016 season in Portugal

125

Abstract no: 308 Presentation at ESCV 2016: Poster 204 Molecular characterization of respiratory syncytial virus during 2015–2016 season in Portugal

126

Abstract no: 311 Presentation at ESCV 2016: Poster 205 Circulating enterovirus genotypes in Norway, 2014–2015: A reason for concern?

126

Abstract no: 312 Presentation at ESCV 2016: Poster 206 Different epidemiological characteristics of respiratory virus infections in children and adults

127

Abstract no: 313 Presentation at ESCV 2016: Poster 207 Presence of human bocavirus 1 and other viral co-infections in hospitalized children with lower respiratory tract infection in Latvia

127

Abstract no: 316 Presentation at ESCV 2016: Poster 208 Molecular epidemiology of circulating human coronaviruses in children at a tertiary hospital in Catalonia (Spain) from 2014 to 2016

128

Abstract no: 319 Presentation at ESCV 2016: Poster 209 No substantial circulation of enterovirus D68 in patients with severe respiratory disease in South-eastern Spain (Valencian Community) during the 2015–2016 influenza season

128

Abstract no: 321 Presentation at ESCV 2016: Poster 210 Genetic variability of human metapneumovirus A strain circulating in Catalonia during the 2014–2015 and 2015–2016 seasons: A 180-nucleotide G gene duplication reported

129

Abstract no: 325 Presentation at ESCV 2016: Poster 211 Respiratory viruses in patients with acute respiratory infections in the pediatric and adults intensive care units

129

Abstract no: 332 Presentation at ESCV 2016: Poster 212 Identification of mutations in surface glycoprotein genes of human respiratory syncytial virus in children treated with palivizumab

130

Abstract no: 340 Presentation at ESCV 2016: Poster 213 The use of in vitro human airway epithelia for the development of novel antivirals

130

Abstract no: 346 Presentation at ESCV 2016: Poster 214 Study on immunological characteristics of monoclonal antibodies produced against the Kazakhstan isolates of influenza A(H1N1) virus

131

Abstract no: 38 Presentation at ESCV 2016: Poster 215 Genetic diversity and characteristics of porcine reproductive and respiratory syndrome virus in the area of Korea from 2013 to 2015

131

Abstract no: 42 Presentation at ESCV 2016: Poster 216 Cluster of severe influenza infections in a smoke-related environment

132

Abstract no: 61 Presentation at ESCV 2016: Poster 217 Prevalence of influenza virus types A and B in patients with acute respiratory infection: 2002–2015

132

Abstract no: 62 Presentation at ESCV 2016: Poster 218 Surveillance of a severe A(H1N1)pdm09 dominated influenza season in N. Greece, 2015–2016

133

Abstract no: 69 Presentation at ESCV 2016: Poster 219 Enhancement of respiratory virus isolation from specimens using centrifugation and interferon inhibitors

133

Abstract no: 74 Presentation at ESCV 2016: Poster 220 Molecular characterisation of human coronaviruses from patients with respiratory disease in Slovenia

133

Abstract no: 78 Presentation at ESCV 2016: Poster 221 Rapid diagnosis of respiratory viral infections in primary health care

134

Abstract no: 82 Presentation at ESCV 2016: Poster 222 False-negative detection of respiratory syncytial virus as an example that regular update of RT-PCR is required for reliable molecular detection of respiratory viruses

134

Abstract n◦: 84 Presentation at ESCV 2016: Poster 223 Genetic characterization of human respiratory syncytial virus (hRSV) infecting children in France during two winter seasons

135

Abstract n◦: 90 Presentation at ESCV 2016: Poster 224 Measles virus-specific IgG and neutralizing antibodies in South Korean

136

Abstract no: 165 Presentation at ESCV 2016: Poster 225 Antiviral effect of hydroxyurea on B19V replication

136

Abstract no: 26 Presentation at ESCV 2016: Poster 226 A modern sub-lingual immunotherapy for neutralization of EBV

136

Abstract no: 310 Presentation at ESCV 2016: Poster 227 Evaluation of the antiviral activity of an aqueous extract fromSolidago virgaurea against Herpes simplex virus type 2

137

Abstract no: 88 Presentation at ESCV 2016: Poster 228 Ex vivo expansion of human cytomegalovirus specific T cells for adoptive transfer therapy of patients after hematopoietic stem cell transplantation – Optimization of cultivation conditions

137

Abstract no: 145 Presentation at ESCV 2016: Poster 229 False-negative parvovirus B 19 serology in pregnancy. Do we need PCR testing to detect or exclude infection?

138

Abstract no: 226 Presentation at ESCV 2016: Poster 230 Human cytomegalovirus (HCMV) genotyping in congenital infection

138

Abstract no: 36 Presentation at ESCV 2016: Poster 231 Practical experience in laboratory diagnosis of congenital CMV infection over a period of 8 years in Slovakia

138

Abstract no: 102 Presentation at ESCV 2016: Poster 232 Study of enterovirus and parechovirus infections in young children in Spain over a 3-year period

139

Abstract no: 139 Presentation at ESCV 2016: Poster 233 Evaluation of viral etiology in central nervous system infections for seven years

139

Abstract no: 183 Presentation at ESCV 2016: Poster 234 CSF: Is it possible to exclude viral infection by cell count, protein or glucose measurement

140

Abstract no: 223 Presentation at ESCV 2016: Poster 235 Congenital rubella syndrome in a country with high vaccination coverage – Portugal

140

Abstract no: 258 Presentation at ESCV 2016: Poster 236 Herpes simplex virus DNA results of cerebrospinal fluid samples by real-time PCR

141

Abstract no: 276 Presentation at ESCV 2016: Poster 237 DNA detection of herpetic viruses in dried blood spots in children with autism spectrum disorders

141

Abstract no: 13 Presentation at ESCV 2016: Poster 238 Aberrant expression of miR-21, miR-376c miR-145 and their target host genes in Merkel cell polyomavirus-positive non-small cell lung cancer

142

Abstract no: 134 Presentation at ESCV 2016: Poster 239 Establishment and characterization of an in vitro model of human Polyomavirus BK (BKV) infected prostate normal cells

142

Abstract no: 193 Presentation at ESCV 2016: Poster 240 Acute exudative tonsillopharyngitis; Epstein-Barr virus, Herpesvirus and Adenovirus

143

Abstract no: 216 Presentation at ESCV 2016: Poster 241 Epilepsy patients show reactivation of the HHV6 infection

143

Abstract no: 218 Presentation at ESCV 2016: Poster 242 High frequency of JC human polyomavirus in Portuguese wastewaters: A possible source for human infection

144

Abstract no: 282 Presentation at ESCV 2016: Poster 243 An unusual course of parvovirus B19 infection, strongly suggestive of virus reactivation

144

Abstract no: 343 Presentation at ESCV 2016: Poster 244 Parvovirus B19: Its real disease associations

144

Abstract no: 51 Presentation at ESCV 2016: Poster 245 Occurrence, phase and status of human parvovirus B19 infection in patients with myalgic encephalomyelitis/chronic fatigue syndrome

145

Abstract no: 6 Presentation at ESCV 2016: Poster 246 EBV and numerous associated diseases

146

Abstract no: 8 Presentation at ESCV 2016: Poster 247 Investigation of malignancy associated with EBV (Epstein-barr virus) in paediatric patients with liver transplant

146

Copyright Information

147

Publication Information

148

European Society for Clinical Virology Application for Membership

149